Key Findings
The Asia Pacific Point of care diagnostic market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 with a CAGR of 10.82% during the forecast period of 2019-2027.

Market Insights
The countries like China, India, Japan, South Korea and Australia are considered fr the market analysis. Factors such as limited resource usability coupled with increasing prevalence rates, and technological advancements, are the major drivers in Asia Pacific segment of point of care testing market which is expected to witness the fastest growth over the forecast period. Japan is one of the largest market for in vitro diagnostics and the popularity of point of care testing has increased due to the focus towards benefits of in vitro diagnostics.

Competitive Insights
F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Quest Diagnostics Inc., Bio-Rad Laboratories, Inc., Biom?rieux SA, Danaher Corporation, Abbott, Chembio Diagnost ICS Systems, Inc., Becton Dickinson and Company, Gene POC, Trinity Biotech, Siemens Healthineers, Trivitron Healthcare, Sight Diagnostics Ltd., Ortho Clinical Diagnostics, and Cardinal Health Inc. are the major companies.